Pharmacological Study of High Doses of Ceftriaxone in Meningitidis
This study is currently recruiting participants.
Verified December 2012 by Nantes University Hospital
Sponsor:
Nantes University Hospital
Information provided by (Responsible Party):
Nantes University Hospital
ClinicalTrials.gov Identifier:
NCT01745679
First received: December 4, 2012
Last updated: December 10, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of the study is to describe the concentrations of Ceftriaxone at the steady state, in patients treated for meningitis, to determine pharmacokinetic parameters at high dose in this population. Additionally, we aimed to detect adverse effect, especially neurological trouble related to Ceftriaxone toxicity.
| Condition | Intervention | Phase |
|---|---|---|
|
Meningitis Neurological Infections |
Drug: Ceftriaxone treatment |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacokinetics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Health Services Research |
| Official Title: | Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections. |
Resource links provided by NLM:
Further study details as provided by Nantes University Hospital:
Primary Outcome Measures:
- plasmatic concentration of ceftriaxone, measured at the steady state (after 48 hours of treatment at least). [ Time Frame: after at least 48 hours of ceftriaxone treatment ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Neurological troubles [ Time Frame: participants will be followed for the duration of ceftriaxone treatment, an expected average of two weeks ] [ Designated as safety issue: Yes ]Neurological troubles explored by electroencephalogram aiming to diagnose epileptic syndrome.
- clinical evolution [ Time Frame: participants will be followed for the duration of ceftriaxone treatment, an expected average of 2 weeks ] [ Designated as safety issue: No ]Time of return to apyrexia, health complications and lenght of hospital stay will be registered.
| Estimated Enrollment: | 200 |
| Study Start Date: | December 2012 |
| Estimated Study Completion Date: | January 2015 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Ceftriaxone treatment
ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
|
Drug: Ceftriaxone treatment
ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
|
Detailed Description:
Day 0 : onset of treatment by Ceftriaxone, following usual therapeutic process (French Guideline) From Day 0 to Day 4 : inclusion, clinical and biological data collection, electroencephalogram at baseline.
Two samples for ceftriaxone concentration monitoring :
- Trough concentration of ceftriaxone at steady state
- A random sample (population PK) At the end of ceftriaxone treatment : assessment of tolerance and efficacy of the treatment.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Hospitalized adults patients,
- age equal or above 18
- Patients with Community or surgical acquired neurological infections, meningitis and others
- Prescription of ceftriaxone >75mg/kg/d or >4g/d -
- Subjects affiliated to French health insurance (social security)
- Informed consent form signed
Exclusion Criteria:
- Patient under guardianship
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01745679
Contacts
| Contact: Nathalie ASSERAY, PH | +33 2 40 08 33 16 | nasseray@chu-nantes.fr |
| Contact: dominique NAVAS, PH | +33 2 40 08 41 54 | dominique.navas@chu-nantes.fr |
Locations
| France | |
| Nantes Universitary Hospital | Recruiting |
| Nantes, Loire Atlantique, France, 44093 | |
| Contact: Nathalie ASSERAY, PH +33 2 40 08 33 16 nasseray@chu-nantes.fr | |
| Principal Investigator: Nathalie ASSERAY, PH | |
| Angers Universitary Hospital | Recruiting |
| Angers, France, 49933 | |
| Contact: Pierre PiAbgueguen, PH PiAbgueguen@chu-angers.fr | |
| Principal Investigator: Pierre ABGUEGUEN, PH | |
| La Roche/Yon hospital | Recruiting |
| La Roche/Yon, France, 85925 | |
| Contact: Thomas GUIMARD, PH thomas.guimard@chd-vendee.fr | |
| Principal Investigator: Thomas GUIMARD, PH | |
| Poitiers Universitary hospital | Recruiting |
| Poitiers, France, 86021 | |
| Contact: France ROBLOT, PU-PH f.roblot@chu-poitiers.fr | |
| Principal Investigator: France ROBLOT, PU-PH | |
| Rennes Universitary hospital | Recruiting |
| Rennes, France, 35033 | |
| Contact: Pierre TATTEVIN, PH +33 2 99 28 43 21 pierre.tattevin@chu-rennes.fr | |
| Principal Investigator: Pierre TATTEVIN, PH | |
| St Nazaire hospital | Recruiting |
| St Nazaire, France, 44600 | |
| Contact: Jérôme HOFF, PH j.hoff@ch-saintnazaire.fr | |
| Principal Investigator: Jérôme HOFF, PH | |
| Tours universitary hospital | Recruiting |
| Tours, France, 37170 | |
| Contact: Louis BERNARD, PU-PH garot@med.univ-tours.fr | |
| Principal Investigator: Louis BERNARD, PU-PH | |
Sponsors and Collaborators
Nantes University Hospital
More Information
No publications provided
| Responsible Party: | Nantes University Hospital |
| ClinicalTrials.gov Identifier: | NCT01745679 History of Changes |
| Other Study ID Numbers: | RC12-0171 |
| Study First Received: | December 4, 2012 |
| Last Updated: | December 10, 2012 |
| Health Authority: | France:ANSM |
Keywords provided by Nantes University Hospital:
|
Ceftriaxone Adverse drug effects Therapeutic monitoring Meningitis |
Additional relevant MeSH terms:
|
Meningitis Central Nervous System Infections Central Nervous System Diseases Nervous System Diseases Ceftriaxone |
Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 17, 2013